Last reviewed · How we verify
NCT07003269
Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
trial testing Hetrombopag in Thalassemia in Children in 30 participants. Enrolling by invitation.
30 April 2026
Quick facts
| Lead sponsor | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 September 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hetrombopag — full drug profile →
Conditions studied
- Thalassemia in Children — all drugs for Thalassemia in Children →
Sponsor
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Who can join
Adults 2 to 17, any sex, with Thalassemia in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to investigate the long-term effects of Hetrombopag in promoting platelet engraftment during haploidentical hematopoietic stem cell transplantation (HSCT) in children with thalassemia, with a specific focus on a 28-day time window post-transplantation. The core question to be addressed is: Is Hetrombopag safe and effective for platelet engraftment in children with thalassemia undergoing haploidentical HSCT within a 28-day post-transplant period? Subjects who received Hetrombopag as part of routine care for haploidentical HSCT in children with thalassemia will be required to complete a 28-day online survey on platelet engraftment outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07003269
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hetrombopag
Trials testing the same drug.
- NCT07492693 — Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors · Phase 2 · recruiting
- NCT06818916 — Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma · NA · recruiting
- NCT06562738 — Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia · Phase 4 · recruiting
- NCT06099925 — The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With · Phase 2 · unknown
- NCT06036966 — The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in · Phase 2 · unknown
Other recruiting trials for Thalassemia in Children
Currently open trials in the same condition.
- NCT05426252 — Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia · Phase 1, PHASE2 · recruiting
Other Haikou Affiliated Hospital of Central South University Xiangya School of Medicine trials
Trials by the same sponsor.
- NCT07018804 — Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome · NA · enrolling by invitation
- NCT07003256 — Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07003269 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07003269.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing